NURIX THERAPEUTICS INC (NRIX) Fundamental Analysis & Valuation

NASDAQ:NRIX • US67080M1036

Current stock price

15.04 USD
-0.57 (-3.65%)
At close:
15.04 USD
0 (0%)
After Hours:

This NRIX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NRIX Profitability Analysis

1.1 Basic Checks

  • In the past year NRIX has reported negative net income.
  • In the past year NRIX has reported a negative cash flow from operations.
  • NRIX had negative earnings in each of the past 5 years.
  • In the past 5 years NRIX always reported negative operating cash flow.
NRIX Yearly Net Income VS EBIT VS OCF VS FCFNRIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M -250M

1.2 Ratios

  • NRIX has a Return On Assets (-38.43%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -49.09%, NRIX is in the better half of the industry, outperforming 65.51% of the companies in the same industry.
Industry RankSector Rank
ROA -38.43%
ROE -49.09%
ROIC N/A
ROA(3y)-35.94%
ROA(5y)-35.14%
ROE(3y)-52.54%
ROE(5y)-50.25%
ROIC(3y)N/A
ROIC(5y)N/A
NRIX Yearly ROA, ROE, ROICNRIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 100 200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NRIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRIX Yearly Profit, Operating, Gross MarginsNRIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. NRIX Health Analysis

2.1 Basic Checks

  • NRIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NRIX has more shares outstanding
  • NRIX has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for NRIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NRIX Yearly Shares OutstandingNRIX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NRIX Yearly Total Debt VS Total AssetsNRIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • NRIX has an Altman-Z score of 4.07. This indicates that NRIX is financially healthy and has little risk of bankruptcy at the moment.
  • NRIX's Altman-Z score of 4.07 is fine compared to the rest of the industry. NRIX outperforms 69.75% of its industry peers.
  • There is no outstanding debt for NRIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.07
ROIC/WACCN/A
WACC8.92%
NRIX Yearly LT Debt VS Equity VS FCFNRIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 7.02 indicates that NRIX has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 7.02, NRIX is doing good in the industry, outperforming 68.98% of the companies in the same industry.
  • A Quick Ratio of 7.02 indicates that NRIX has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 7.02, NRIX is in the better half of the industry, outperforming 68.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.02
Quick Ratio 7.02
NRIX Yearly Current Assets VS Current LiabilitesNRIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NRIX Growth Analysis

3.1 Past

  • NRIX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.19%.
  • NRIX shows a strong growth in Revenue. In the last year, the Revenue has grown by 53.95%.
  • NRIX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.35% yearly.
EPS 1Y (TTM)-5.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.33%
Revenue 1Y (TTM)53.95%
Revenue growth 3Y29.54%
Revenue growth 5Y36.35%
Sales Q2Q%2.21%

3.2 Future

  • Based on estimates for the next years, NRIX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.79% on average per year.
  • NRIX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.03% yearly.
EPS Next Y-2.29%
EPS Next 2Y0.88%
EPS Next 3Y6.31%
EPS Next 5Y14.79%
Revenue Next Year-26.71%
Revenue Next 2Y-3.78%
Revenue Next 3Y17.29%
Revenue Next 5Y42.03%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NRIX Yearly Revenue VS EstimatesNRIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
NRIX Yearly EPS VS EstimatesNRIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. NRIX Valuation Analysis

4.1 Price/Earnings Ratio

  • NRIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NRIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRIX Price Earnings VS Forward Price EarningsNRIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRIX Per share dataNRIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.88%
EPS Next 3Y6.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NRIX Dividend Analysis

5.1 Amount

  • NRIX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NRIX Fundamentals: All Metrics, Ratios and Statistics

NURIX THERAPEUTICS INC

NASDAQ:NRIX (3/13/2026, 8:00:02 PM)

After market: 15.04 0 (0%)

15.04

-0.57 (-3.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-28
Earnings (Next)04-06
Inst Owners102.75%
Inst Owner Change30.67%
Ins Owners1.12%
Ins Owner Change0.76%
Market Cap1.55B
Revenue(TTM)83.98M
Net Income(TTM)-264.46M
Analysts86.09
Price Target30.6 (103.46%)
Short Float %15.27%
Short Ratio12.8
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.19%
Min EPS beat(2)-20.05%
Max EPS beat(2)7.66%
EPS beat(4)3
Avg EPS beat(4)7.92%
Min EPS beat(4)-20.05%
Max EPS beat(4)30.11%
EPS beat(8)5
Avg EPS beat(8)3.51%
EPS beat(12)8
Avg EPS beat(12)3.66%
EPS beat(16)9
Avg EPS beat(16)2.42%
Revenue beat(2)0
Avg Revenue beat(2)-30.37%
Min Revenue beat(2)-53.76%
Max Revenue beat(2)-6.97%
Revenue beat(4)2
Avg Revenue beat(4)33.88%
Min Revenue beat(4)-53.76%
Max Revenue beat(4)153.94%
Revenue beat(8)4
Avg Revenue beat(8)11.32%
Revenue beat(12)7
Avg Revenue beat(12)7.63%
Revenue beat(16)9
Avg Revenue beat(16)1.64%
PT rev (1m)0%
PT rev (3m)10.39%
EPS NQ rev (1m)2.53%
EPS NQ rev (3m)10.47%
EPS NY rev (1m)1.39%
EPS NY rev (3m)7.96%
Revenue NQ rev (1m)-1.74%
Revenue NQ rev (3m)-5.8%
Revenue NY rev (1m)5.56%
Revenue NY rev (3m)11.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.42
P/FCF N/A
P/OCF N/A
P/B 2.87
P/tB 2.87
EV/EBITDA N/A
EPS(TTM)-3.04
EYN/A
EPS(NY)-3.11
Fwd EYN/A
FCF(TTM)-2.56
FCFYN/A
OCF(TTM)-2.43
OCFYN/A
SpS0.82
BVpS5.24
TBVpS5.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -38.43%
ROE -49.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.94%
ROA(5y)-35.14%
ROE(3y)-52.54%
ROE(5y)-50.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 160.21%
Cap/Sales 16.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.02
Quick Ratio 7.02
Altman-Z 4.07
F-Score5
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)123.75%
Cap/Depr(5y)160.58%
Cap/Sales(3y)14.86%
Cap/Sales(5y)19.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.33%
EPS Next Y-2.29%
EPS Next 2Y0.88%
EPS Next 3Y6.31%
EPS Next 5Y14.79%
Revenue 1Y (TTM)53.95%
Revenue growth 3Y29.54%
Revenue growth 5Y36.35%
Sales Q2Q%2.21%
Revenue Next Year-26.71%
Revenue Next 2Y-3.78%
Revenue Next 3Y17.29%
Revenue Next 5Y42.03%
EBIT growth 1Y-34.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.61%
EBIT Next 3Y-1.2%
EBIT Next 5YN/A
FCF growth 1Y-44.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.55%
OCF growth 3YN/A
OCF growth 5YN/A

NURIX THERAPEUTICS INC / NRIX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NURIX THERAPEUTICS INC (NRIX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to NRIX.


What is the valuation status of NURIX THERAPEUTICS INC (NRIX) stock?

ChartMill assigns a valuation rating of 0 / 10 to NURIX THERAPEUTICS INC (NRIX). This can be considered as Overvalued.


What is the profitability of NRIX stock?

NURIX THERAPEUTICS INC (NRIX) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for NRIX stock?

The Earnings per Share (EPS) of NURIX THERAPEUTICS INC (NRIX) is expected to decline by -2.29% in the next year.